SeerPharma Pty Ltd :: DISCover web-based training

Breast Cancer: Diagnosis

Description: Breast cancer is the most common form of cancer in North American women. Although the incidence of breast cancer has been increasing every year, early screening programs in some countries have reduced the number of deaths caused by breast cancer. This course explains the methods used to detect and diagnose breast cancer, and explains the prognostic value of the diagnostic tests. and then covers two different case studies in in which this information is applied.

COURSE OUTLINE

INTRODUCTION
1. Course Information
2. Interface Tour
3. Course Overview

DIAGNOSTIC PROCEDURES
4. Objectives
5. Physical Examination
6. Mammography
7. Confirmation
8. Progress Check

CASE STUDIES
9. Premenopausal Breast Cancer
10. Postmenopausal Breast Cancer

STAGING AND GRADING
9. Objectives
10. TNM System
11. Tumor Grade
12. Progress Check

MOLECULAR DIAGNOSTICS
13. Objectives
14. HER-2 Status and Other Indications
15. Estrogen Receptor Status
16. Progress Check

CONCLUSION
17. Summary

COURSE OBJECTIVES

Students completing this course should be able to:

List the symptoms of a breast cancer patient
Describe screening and diagnostic procedures
Explain how mammography is used to diagnose breast cancer
Explain the TNM scale and describe how it is used in staging breast cancers
Apply the TNM system
Understand the concept of tumor grade and its prognostic value
Understand the concept of molecular diagnostics and its utility for the treatment of breast cancer
Understand how a cancer’s HER-2 status affects treatment
List two techniques for determining the HER-2 status of a tumor
Understand how a tumor’s estrogen receptor (ER) status affects treatment

Home

Training Programs

Upcoming Training

Compliance Consulting

DISCover e-Learning

Modules available

SOPtrain

Quality Management Software

Clinical Trials Software

SeerPharma has partnered with GeneEd to now distribute courses in Major Therapeutic Areas, Clinical Research, and Biotechnology & Genetics.